trial · primary record
Shingrix
Herpes Zoster
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 225 |
| Primary completion | 2027-10-01 |
| Primary endpoint | Fold change of anti-gE antibody concentrations evaluated regularly through the end of study (months 3 and 12) by CD4 count (= 300) |
| Registry ID | NCT05580458 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:33:29.053Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05580458
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.